ANI Pharmaceuticals (ANIP)

[auh2oman]

Informative Article on Delivering to Rare Disease Patients ...

Below is an excerpt from the article pertaining to ANI Pharmaceuticals ability to deliver to this market:

Data can pinpoint the path forward, even when patient journeys are complex and varied (like in rare autoimmune diseases). In North America, end-to-end patient data is increasingly used to map the most likely patient pathways from diagnosis to treatment. For example, ANI Pharmaceuticals used advanced customer segmentation and technology to build specialised field teams in months, empowering them with information on different patient segments, therapeutic areas, and HCP customers. Field teams succeed because they prioritise engagement based on which doctors have the most appropriate patient visits and what they tend to prescribe.

https://pharmaphorum.com/sales-marketing/delivering-5-10000-patients-rare-disease

It will be interesting to see if it's reflexed positively in the Cortrophin sales numbers to be released in the 4th Quarter and Full Year 2022 Financial Results.

Good Luck!